



Press Release

Dynacure appoints its Management Team and members of the Board of Directors

Strasbourg (France), March 9, 2017

Dynacure is a biotechnology company developing new treatments for patients affected by serious orphan disorders. In its first drug discovery program, Dynacure is focusing on Centronuclear Myopathies (CNM), a debilitating rare disease affecting children and young adults. Dynacure's development program is using an antisense oligonucleotide developed in collaboration with Ionis Pharmaceuticals. The company was founded in 2016 as a spin-off from the IGBMC (Institute of Genetic and Molecular and Cellular Biology – Unistra/INSERM/CNRS) of Strasbourg. Dynacure today announces the appointment of its new Management Team and members of the Board of Directors.

Experienced management team to develop new therapeutics in rare diseases

Dynacure's leadership team includes Stephane van Rooijen (CEO), Frédéric Legros (COO) and Leen Thielemans (Head of Development). The team will focus on the company's preclinical and clinical development programs in CNM and the expansion of its pipeline in rare disease treatments.

Stephane van Rooijen (MD MBA), Chief Executive Officer

Stephane has an extensive experience in the life sciences orphan biotech industry, previously working at Genzyme, Viropharma-Shire and Confo Therapeutics. He has a medical degree from the University of Leuven in Belgium and obtained an MBA at the Erasmus University Rotterdam and Georgetown University of Washington DC.

Frédéric Legros (PhD), Chief Operating Officer

Frédéric has over a decade of experience in business development and strategic management. Before joining Dynacure, Frédéric was Vice President and Corporate Head of Business Development at Valneva SE. Frédéric obtained his PhD in molecular biology in 2002 at the Institute of Myology in Paris. He also holds a business degree from NEOMA business school, France.

Leen Thielemans (PhD), Head of Development

Leen brings with her over fifteen years of experience in pharmaceutical R&D, from drug discovery to early clinical development. Leen previously worked at Johnson & Johnson, 4AZA-Elbion, Movetis, and Shire. Leen Thielemans is a bio-engineer from the University of Leuven and an epidemiologist with a PhD in medical sciences

Recognized leaders of the life sciences industry join the board of directors

Dynacure's Board of Directors has six members: Frederic Chereau, Chris Mirabelli and Brett Monia, who have been appointed as independent directors, Rémi Droller and Vanessa Malier, who represent Kurma Partners, and Stephane van Rooijen (CEO).

Frederic Chereau, President and CEO of LogicBio

Frederic has over 25 years of experience and acknowledged leadership in the orphan life sciences industry and previously worked at aTyr, Shire, Pervasis and Genzyme. He holds a B.S. in Physics from Paris University and obtained a Master's degree in Management from La Rochelle Business School in France and an M.B.A. from INSEAD, Fontainebleau, France.

Chris Mirabelli (PhD), CEO and Chairman of the Board of Directors of Leap Therapeutics

Chris is an internationally-recognized biotech entrepreneur, was a co-founder of Ionis Pharmaceuticals and currently holds board positions in a number of US biotechnology companies. He received his PhD in Molecular Pharmacology from the Baylor College of Medicine and obtained a B.S. degree in Biology from the State University of New York at Fredonia.

Brett Monia (PhD), Senior Vice President of Antisense Drugs Discovery at Ionis Pharmaceuticals

Brett is a founding member of Ionis, he is the Franchise Leader for programs in Oncology and Rare Genetic Diseases, and head of Drug Discovery at Ionis Pharmaceuticals. Dr. Monia received his PhD in Pharmacology at the University of Pennsylvania and holds B.S. degrees in Molecular Biology and Analytical Chemistry.

Remi Droller, Chairman of Dynacure's Board of Directors said: *"We are very proud of the creation of this new rare disease biotech company, which is the result of cooperation between several major players in the life sciences field. With the expertise of its management, board of directors and Ionis Pharmaceuticals antisense platform, Dynacure is ready to deliver its development targets."*

Stephane van Rooijen, CEO of Dynacure added: *"Dynacure is well positioned to drive forward its lead program in Centronuclear Myopathies. We now plan to focus on the expansion of our portfolio in order to develop new therapeutic approaches and help patients who suffer from rare debilitating diseases."*

- END -

About Dynacure: www.dynacure.fr

Dynacure is a biotechnology company developing new treatments for patients affected by serious orphan disorders. In its first drug discovery program, Dynacure is focusing on Centronuclear Myopathies (CNM), a rare, debilitating disease affecting children and young adults. Dynacure's Dyn101 development program is based on the modulation of the expression of the Dynamin 2 protein through the use of an antisense oligonucleotide developed in collaboration with Ionis Pharmaceuticals, the leading biopharmaceutical company in RNA-targeted drug discovery.

Dynacure was founded in 2016 as a spin-off from the IGBMC (Institute of Genetic and Molecular and Cellular Biology – Unistra/INSERM/CNRS) of Strasbourg.

Contact:

NewCap – Media Relations

Nicolas Merigeau
nmerigeau@newcap.fr
+33(0)1 44 71 94 98

Dynacure

Stephane van Rooijen, CEO
info@dynacure.fr

Management team biographies

Stephane van Rooijen (MD, MBA) is a general management biotech executive with in-depth experience in life sciences working with European and North American organizations. He studied medicine at KU Leuven and obtained an MBA at Erasmus University Rotterdam and Georgetown University, Washington DC. He joined Dynacure in 2016 as Chief Executive Officer.

Stephane started his career at Arthur D. Little on the strategy consultant team. After joining Genzyme Corporation (2004, Amsterdam/Brussels) and working in business development and finance, he became the European Cardiovascular Business Unit Leader, where he managed cross-functional business unit teams and early and late-stage portfolios, launched new products and managed P&Ls. In 2012, he joined Viropharma (London) as a member of its European Business Council and global pipeline project team, where he was responsible for leading the company's main commercial program, Cinryze (orphan drug indicated for hereditary angioedema), building infrastructure, driving geographic expansion and partnerships and supporting R&D pipeline development. In 2014, as founding CEO of Confo Therapeutics (VIB-VUB spin-off), he set up the company, raised funding, recruited an outstanding team and led the companies' expansion to build a portfolio of drug development programs.

Frédéric Legros (PhD) is an experienced business professional with a passion for life sciences and business. He has over a decade of experience in licensing and business development. He studied biotechnology at AgroParisTech, obtained his PhD in molecular biology (2002), and published several publications in peer-reviewed journals while at the Institute of Myology (Paris). He also holds a business degree from NEOMA Business School, France (2003). Frédéric joined Dynacure in January 2017 as Chief Operating Officer.

Before joining Dynacure, Frédéric was Vice President and Corporate Head of Business Development of Valneva SE, a company listed on the French stock exchange, where he developed and commercialized vaccines. Frédéric served on the board of directors of French biotechnology company Blink Biomedical, which is dedicated to the development of novel antibodies in the field of immune checkpoint targets in cancer. Frédéric was also Director of the Pasteur Institute's Tech Transfer office, where he was in charge of the licensing portfolio and strategic partnerships.

Leen Thielemans (PhD) is a bio-engineer and epidemiologist with a PhD in medical sciences and over 15 years of experience in pharmaceutical R&D, ranging from drug discovery to early clinical development. She joined Dynacure as Head of Development.

Leen's career brought her to various prominent companies: Johnson & Johnson, 4AZA-Elbion, Movetis, and Shire. The scope of her discovery and early clinical development work was widened from immune-suppressive compounds, gastroenterology, COPD, and hepatology. She also built up experience with the implementation of patient reported outcomes, as well as the testing of biomarkers. Following the integration of Movetis into Shire, Leen Thielemans was cofounder of 2Bridge, the life science development service company.

Board member biographies

Frederic Chereau currently serves as President and Chief Executive Officer of LogicBio Therapeutics. From 2014 to 2015, Mr. Chereau was President and Chief Operating Officer of aTyr Pharma (LIFE). During his tenure, the company advanced multiple programs to clinical stage and successfully completed private financing and an IPO. Prior to that, Mr. Chereau was Senior Vice President and Angioedema Franchise Lead at Shire (SHPG), where he defined and oversaw the execution of the global strategy for the franchise, positioning it as the leader on its market. From 2008 to 2012, as President and Chief Executive Officer of Pervasis Therapeutics, he led the company through key strategies leading up to the acquisition of the company by Shire. Before Pervasis, Mr. Chereau worked at Genzyme from 1999 to 2008, where he held roles with increasing responsibility, initially within Genzyme France and Genzyme Europe, and achieved the position of Vice President and General Manager of the Cardiovascular Business Unit at Genzyme Corporation. Prior to Genzyme, he started his career at Hemotech, where he held sales and marketing roles. Mr. Chereau serves as a member of the Comité Stratégique d'Orientation at La Rochelle Business School. He holds a B.S. in Physics from Paris University, received his Master's degree in management from La Rochelle Business School in France and received an MBA from INSEAD, Fontainebleau, France and Singapore.

Rémi Droller has a Master's degree in Molecular Biology (Paris VI) and Master's degree in Finance and Innovation Management (Masternova - AgroPariTech). He started at CDC Innovation from 2000 to 2003 and later joined AGF Private Equity (now Idinvest Partners), where he developed investment activity in life sciences and made investments such as Novagali Pharma (listed on Euronext and acquired by Santen), Prosensa Therapeutics (listed on Nasdaq and acquired by Biogen), Vivacta (acquired by Novartis), IntegraGen (listed on Alternext) and Onxeo (listed on Euronext). Rémi joined Kurma Partners in 2010 and is in charge of investments at AM Pharma (The Netherlands), Orphazyme (Denmark), Oxthera (Sweden), Stat Diagnostica (Spain), Step Pharma (France), and Zealand Pharma (Denmark).

Vanessa Malier, who has a scientific background, started her career at the Paris-based VC fund CDC Innovation in 1998 as an analyst. Afterwards, she joined a California-based start-up, where she was in charge of business development activities. Vanessa then joined Ipsen in 2003 as Strategic Advisor to the CEO, where she headed the portfolio management team for the gastroenterology product range. In 2005, Vanessa was appointed Product Manager and Team Leader for febuxostat (Adenuric), which received EMA approval in 2008. Vanessa was then successively appointed as Senior Director, Business Development Oncology in 2009 and VP, R&D Strategic Planning in 2011. Vanessa graduated in Biology at Ecole Normale Supérieure, Cachan and in Immunology at the Pasteur Institute. Vanessa joined Kurma in 2013 and is responsible for the investment in Xeltis (Switzerland).

Chris Mirabelli (PhD) has served as the Chairman of the Board of Directors of Leap Therapeutics (LPTX) since 2016 and has also served as the President and Chief Executive Officer since the company's inception in 2011. Dr. Mirabelli has been a Managing Director of HealthCare Ventures LLC since 2000. From December 1999 to May 2000, Dr. Mirabelli served as President of Pharmaceutical Research and Development and as a member of the Board of Directors of Millennium Pharmaceuticals following its merger with LeukoSite, where Dr.

Mirabelli had been serving as President, Chief Executive Officer and Chairman of the Board of Directors since the company's inception in 1993. He was a cofounder of Ionis Pharmaceuticals, Inc. (IONS), where he held several positions, including Senior Vice President of Research, from 1989 until 1993. Dr. Mirabelli started his career at SmithKline and French Laboratories (now part of GlaxoSmithKline Plc) in the R&D Division. He is a member of the board of advisors of the Blavatnik Biomedical Accelerator Fund at Harvard Medical School and the Boston Biomedical Innovation Center. Dr. Mirabelli is a member of the Board of Trustees of Guilford College. He received his PhD in Molecular Pharmacology from Baylor College of Medicine and a B.S. in Biology from State University of New York at Fredonia.

Brett P. Monia (PhD) is a founding member of Ionis Pharmaceuticals (IONS) and the Executive Officer and Senior Vice President of Antisense Drug Discovery. Dr. Monia is also the Franchise Leader for programs in Oncology and Rare Genetic Diseases at Ionis Pharmaceuticals. As head of Drug Discovery, Dr. Monia is responsible for establishing strategic directions for preclinical drug discovery research, establishing and supervising early clinical development strategies through clinical proof-of-concept and coordinating research activities with clinical investigators, consultants, and corporate partners. Programs under Dr. Monia's supervision have resulted in the clinical development of more than 25 antisense-based drugs to date across a broad range of therapeutic areas, including multiple marketing approvals. Dr. Monia's publication record exceeds more than 200 research manuscripts, reviews, and book chapters, and he is the inventor of more than 100 issued patents. Dr. Monia received his PhD in Pharmacology at the University of Pennsylvania and holds B.S. degrees in Molecular Biology and Analytical Chemistry. He serves on the editorial boards for numerous scientific journals, serves on the Board of Directors as Immediate Past President of the Oligonucleotide Therapeutics Society and is an adjunct professor of biology at San Diego State University.

Contact:

NewCap – Media Relations

Nicolas Merigeau
nmerigeau@newcap.fr
+33(0)1 44 71 94 98

Dynacure

Stephane van Rooijen, CEO
info@dynacure.fr